Yang Rui arrived at Astra's office half an hour early, and sat quietly in the lounge, reading his manuscript.

Giving lectures in large companies is very polarizing, and sometimes some professors get extra praise, and sometimes they get special ridicule.

Having a good title is usually easier to get the former.

For example, a professor at Harvard, a professor at Stanford University, or a fellow of Trinity College, Cambridge, etc., is always more convincing, but not absolutely.

A good example is a professor at Stanford University. Because of the distance, Silicon Valley startups often invite Stanford professors to give lectures, but the people who go are not necessarily recognized by Silicon Valley people. Even though many Silicon Valleyers come from Stanford University's computer science department, they scoff hard. After years or years of hard work, those well-paid Silicon Valley people are no longer what they are in school, and they have their own understanding of the true strength of professors at Stanford University.

At this time, professors at Stanford University are not necessarily at the forefront of the industry.

Moreover, the so-called cutting-edge theories they put forward may not necessarily be recognized by the industry.

Cisco's founders, Bosak and Rena, can be regarded as an example of the industry's all-in-one approach, they are masters of computer theory, and they have made superb practices, and they have created routers that have laid the initial foundation for the development of network technology.

But a closer look at the identities of the two shows that it was not easy for them to do all this. Bosak was the director of the computer center in Stanford's computer science department, and Sandy Rena was the head of the computer center in the business school, and they were basically first-rate scholars in the world of theory during the underdeveloped years of Silicon Valley.

Giving a lecture to Astra is also not an easy task.

For such a large pharmaceutical company, it cannot be regarded simply as the level of the industry. In a company of this level, there is also a hidden dragon and a crouching tiger.

Of course, native pharmaceutical company researchers have no sense of existence in front of scholars like Yang Rui, they belong to the bottom of the scientific research contempt chain, whether they are good students or bad students, whether they are undergraduate or doctoral students, if they enter pharmaceutical companies after graduation, they will basically not make achievements in the frontier of science.

Even in exceptional cases, scientists are not usually recognized by the mainstream.

The goal of pharmaceutical companies is to find compounds for known targets, in the field of G protein-coupled receptors, the main work of scientists in pharmaceutical companies is to pick up a target in systematic research after cutting-edge scientists have done systematic research, as the research object, it can be said that the researchers in the industry are not even second-line scientists, they can only be called third-line, the so-called achievement transformation people.

However, in addition to the original pharmaceutical company researchers, companies like Astra inevitably have first-tier and second-tier researchers, and some powerful companies can even recruit Nobel Prize winners.

The Nobel Prize in Biology in 2008 was awarded to Ralder Hausen for his work on the human* neoplasty virus that causes cervical cancer, and his close association with AstraZeneca can be considered one in three AstraZeneca people.

This Nobel Prize is also the most suspected Nobel Prize fraud case known to Yang Rui - although there is no conclusive evidence, AstraZeneca did play a key role in this Nobel Prize. One of AstraZeneca's directors was a member of the Nobel Prize committee and, before winning the prize, bought a company that develops key components of the HPV vaccine and will charge huge royalties for it.

In addition, the chairman of the five-member committee responsible for selecting the Nobel Prize candidates, who served as AstraZeneca's paid adviser in '06, was one of the members of the 50-member committee responsible for voting, and also took AstraZeneca's money in the name of the consultant.

In addition to AstraZeneca's sponsorship of two Nobel committee agencies and its subordinate promotion departments in the years before that, several members of the Nobel Prize committee admitted to being invited to China at the expense of the Chinese side to explain to Chinese officials how the candidates were selected - that was after 05 years, indicating that China at that time already had a peep at the Nobel Prize, or, just AstraZeneca used China as a platform.

All in all, Big Pharma, like the big military industry, or the big energy companies, is an organism of enormous energy that can play a stronger role in world affairs than most small governments in Asia, Africa, and Latin America.

But Big Pharma is also a complex complex of contradictions, all of which are decades or even hundreds of years old, and the founders are gone, and it is difficult for the remaining professional managers and shareholders to find a single dominant player, not a director or chairman, who can make a sure decision on a major matter.

Yang Rui needs to prove his strength even more so that he can catch a ride.

Before the Nobel Prize, everyone is equal, except Sweden.

"Mr. Yang Rui, the time is up. Pulitzer came to the break room and spoke in a calm voice.

Yang Rui stood up steadily, smiled, and asked, "Are there many people coming?"

"There were about 60 or so people. Pulitzer explained: "Sweden is a small country, and it is rare to gather a lot of people at once, as China does. ”

Yang Rui was stunned for a moment and couldn't help laughing.

Pulitzer knew he had said the wrong thing, and he couldn't help but feel a little embarrassed.

Yang Rui coughed and said, "60 people are very satisfying." ”

He is ready to explain academic issues to researchers, and there are many people who can get together in a class. To put it mildly, now that an academic seminar on G protein-coupled receptors is held in China, it is estimated that there are not even 30 scholars who can understand what he is talking about, and even worse, fifteen may be barely enough.

Although the royal flag can be seen when you look up, it takes courage and luck to walk under the royal flag with knee-high blood.

More than 60 people sat neatly in a classroom-like conference room, each with a chair, which was also neatly arranged.

It's really neat.

Yang Rui stood on the podium and could see that these chairs were like a military parade, with horizontal and vertical screens.

Moreover, unlike domestic lectures, people will deliberately sit out of the way, or prefer to sit in the back.

The Swedes sat from front to back, from left to right, each chair nervously next to each other.

The chairs are folding chairs, so they don't have handles, which makes the large square chairs a little cramped, but everyone Swede sits upright, chest up, and tries not to make physical contact with other people.

If he hadn't known that this was his own temporary request, Yang Rui would have rehearsed it.

Of course, it can also be said that they were rehearsed, and the Swedes have been managed collectively since childhood.

In addition to the employees of the Astra company, several members of the Chinese delegation came to attend the lecture, and only one row was seated in total.

Yang Rui plans to teach in English, so if he doesn't understand, he won't use it.

In fact, you don't have to come to listen to English to understand it, and the content of Yang Rui's lectures has no intersection with most people's research directions.

"I'm going to talk about G protein-coupled receptors today, and G proteins. Yang Rui spread the handouts on the lectern, and without looking at them, he said: "I want to make a prediction first, by 30 years, drugs targeting G protein-coupled receptors will reach 50% of the total number of modern drugs." In other words, when pharmaceutical companies develop new drugs in the future, at least one of every two new drugs is developed with G protein-coupled receptors as the target......"

The Swedes, who used to be very quiet, are suddenly not so quiet.

As a very disciplined people, the Swedes are very similar to the Japanese, and they are very particular about not causing trouble to others, but at this time, some people can't help but shout, "How is it possible?" ”

This is not a question, and Yang Rui did not have the desire to answer, but continued: "One of the two new drugs targets G protein-coupled receptors, which is actually not enough, because the 50% I said is 50% of the total number of modern drugs...... But let's not talk about the future today, let's talk about the present, what we can do now with G protein-coupled receptors. ”

As soon as Yang Rui said this, everyone quieted down.

For researchers at pharmaceutical companies, "what can be done" is a real thing.

At this time, Yang Rui seemed to be a pig killer. Pharmaceutical companies are in the business of catering. They need to understand how the pig is divided now, and what is the best fit for each part?

In the end, whether the pork ribs are used for soup or sweet and sour, and whether the fatty meat is used for oil refining or returned to the pot, also depends on the quality of the meat.

Of course, it is only the pharmaceutical companies at the level of Astra that are so particular, and it is normal to do it casually.

Yang Rui glanced down at his handout, and then said: "My ion channel laboratory has done in-depth research on G protein-coupled receptors, but this aspect is not what I want to talk about today, I want to start from a new angle, and I will name it dynamic mass retest." This approach, which I thought about in my spare time, is a small problem, but it is very useful, and at the moment, the most appropriate place is that it can analyze the drug effects of G protein-coupled receptors in human primary cells. ”

As soon as the word "drug effect" came out, the neat squares suddenly rose and fell from side to side like waves.

It was the researchers' head-to-ear movements.

……

Long press the text to copy the znmanhua attention public account to watch (bring your own tissues)

Reading chapter: Reborn God-level Scholar_Chapter 1271 Drug Effects

Browse and read the address: